Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters

• Published in: bioRxiv 2021-08
• Main Authors: Kulkarni, Rakesh, Chen, Wen-Ching, Lee, Ying, Chi-Fei Kao, Shiu-Lok Hu, Ma, Hsiu-Hua, Jia-Tsrong, Jan, Chun-Che Liao, Jian-Jong, Liang, Hui-Ying, Ko, Cheng-Pu, Sun, Yin-Shoiou Lin, Yu-Chiuan Wang, Sung-Chan, Wei, Yi-Ling, Lin, Ma, Che, Yu-Chan, Chao, Yu-Chi, Chou, Chang, Wen
• Format: Article
• Language: English
• Subjects: Antibodies; Coronaviruses; COVID-19; Immune response; Infections; Lymphocytes T; Mammalian cells; mRNA; Severe acute respiratory syndrome coronavirus 2; Smallpox; Spike protein; Strains (organisms); Vaccines; Viruses
• DOI: 10.1101/2021.08.03.454910

COVID-19 in humans is caused by Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that belongs to the beta family of coronaviruses. SARS-CoV-2 causes severe respiratory illness in 10-15% of infected individuals and mortality in 2-3%. Vaccines are urgently needed to prevent infection and to contain viral spread. Although several mRNA- and adenovirus-based vaccines are highly effective, their dependence on the cold chain transportation makes global vaccination a difficult task. In this context, a stable lyophilized vaccine may present certain advantages. Accordingly, establishing additional vaccine platforms remains vital to tackle SARS-CoV-2 and any future variants that may arise. Vaccinia virus (VACV) has been used to eradicate smallpox disease, and several attenuated viral strains with enhanced safety for human applications have been developed. We have generated two candidate SARS-CoV-2 vaccines based on two vaccinia viral strains, MVA and v-NY, that express full-length SARS-CoV-2 spike protein. Whereas MVA is growth-restricted in mammalian cells, the v-NY strain is replication-competent. We demonstrate that both candidate recombinant vaccines induce high titers of neutralizing antibodies in C57BL/6 mice vaccinated according to prime-boost regimens. Furthermore, our vaccination regimens generated TH1-biased immune responses in mice. Most importantly, prime-boost vaccination of a Syrian hamster infection model with MVA-S and v-NY-S protected the hamsters against SARS-CoV-2 infection, supporting that these two vaccines are promising candidates for future development. Finally, our vaccination regimens generated neutralizing antibodies that partially cross-neutralized SARS-CoV-2 variants of concern. Competing Interest Statement The authors have declared no competing interest.